23.44 USD
-0.27 (-1.14%)
At close: Feb 6, 2026
23.44 USD
0 (0%)
After Hours: 2/6/2026, 8:00:00 PM
We assign a fundamental rating of 4 out of 10 to FLGT. FLGT was compared to 102 industry peers in the Health Care Providers & Services industry. The financial health of FLGT is average, but there are quite some concerns on its profitability. FLGT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- FLGT had positive earnings in the past year.
- FLGT had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: FLGT reported negative net income in multiple years.
- Each year in the past 5 years FLGT had a positive operating cash flow.
1.2 Ratios
- FLGT has a Return On Assets of -3.54%. This is in the lower half of the industry: FLGT underperforms 62.75% of its industry peers.
- FLGT's Return On Equity of -3.82% is in line compared to the rest of the industry. FLGT outperforms 49.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.54% | ||
| ROE | -3.82% | ||
| ROIC | N/A |
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 41.24%, FLGT is doing good in the industry, outperforming 70.59% of the companies in the same industry.
- In the last couple of years the Gross Margin of FLGT has declined.
- The Profit Margin and Operating Margin are not available for FLGT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
2. Health
2.1 Basic Checks
- FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- FLGT has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for FLGT has been increased compared to 5 years ago.
- The debt/assets ratio for FLGT has been reduced compared to a year ago.
2.2 Solvency
- FLGT has an Altman-Z score of 6.09. This indicates that FLGT is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 6.09, FLGT belongs to the best of the industry, outperforming 91.18% of the companies in the same industry.
- A Debt/Equity ratio of 0.00 indicates that FLGT is not too dependend on debt financing.
- With an excellent Debt to Equity ratio value of 0.00, FLGT belongs to the best of the industry, outperforming 84.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.09 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
- FLGT has a Current Ratio of 7.01. This indicates that FLGT is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of FLGT (7.01) is better than 97.06% of its industry peers.
- FLGT has a Quick Ratio of 7.01. This indicates that FLGT is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of FLGT (7.01) is better than 97.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.01 | ||
| Quick Ratio | 7.01 |
3. Growth
3.1 Past
- FLGT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.27%.
- The Earnings Per Share has been growing by 22.18% on average over the past years. This is a very strong growth
- The Revenue has grown by 13.60% in the past year. This is quite good.
- FLGT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.21% yearly.
EPS 1Y (TTM)-60.27%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-54.84%
Revenue 1Y (TTM)13.6%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%17.18%
3.2 Future
- The Earnings Per Share is expected to decrease by -24.95% on average over the next years. This is quite bad
- The Revenue is expected to grow by 10.99% on average over the next years. This is quite good.
EPS Next Y-41.71%
EPS Next 2Y-63.28%
EPS Next 3Y-32.37%
EPS Next 5Y-24.95%
Revenue Next Year14.59%
Revenue Next 2Y12.14%
Revenue Next 3Y11.38%
Revenue Next 5Y10.99%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- FLGT is valuated quite expensively with a Price/Earnings ratio of 80.83.
- The rest of the industry has a similar Price/Earnings ratio as FLGT.
- When comparing the Price/Earnings ratio of FLGT to the average of the S&P500 Index (27.92), we can say FLGT is valued expensively.
- FLGT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.83 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- FLGT's earnings are expected to decrease with -32.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)3.64
EPS Next 2Y-63.28%
EPS Next 3Y-32.37%
5. Dividend
5.1 Amount
- FLGT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
23.44
-0.27 (-1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2025-11-07/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners57.31%
Inst Owner Change0.42%
Ins Owners32.7%
Ins Owner Change-1.22%
Market Cap724.53M
Revenue(TTM)315.55M
Net Income(TTM)-42.98M
Analysts80
Price Target34.34 (46.5%)
Short Float %8.01%
Short Ratio7.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)149.45%
Min EPS beat(2)137.43%
Max EPS beat(2)161.46%
EPS beat(4)4
Avg EPS beat(4)137.97%
Min EPS beat(4)121.2%
Max EPS beat(4)161.46%
EPS beat(8)8
Avg EPS beat(8)161.48%
EPS beat(12)11
Avg EPS beat(12)118.12%
EPS beat(16)15
Avg EPS beat(16)122.7%
Revenue beat(2)2
Avg Revenue beat(2)3.23%
Min Revenue beat(2)1.21%
Max Revenue beat(2)5.24%
Revenue beat(4)3
Avg Revenue beat(4)1.43%
Min Revenue beat(4)-1.8%
Max Revenue beat(4)5.24%
Revenue beat(8)5
Avg Revenue beat(8)0.7%
Revenue beat(12)9
Avg Revenue beat(12)5.2%
Revenue beat(16)13
Avg Revenue beat(16)7.57%
PT rev (1m)0%
PT rev (3m)32.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)113.43%
EPS NY rev (1m)0%
EPS NY rev (3m)180.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.83 | ||
| Fwd PE | N/A | ||
| P/S | 2.3 | ||
| P/FCF | N/A | ||
| P/OCF | 475.73 | ||
| P/B | 0.64 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.29
EY1.24%
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)0.05
OCFY0.21%
SpS10.21
BVpS36.42
TBVpS31.24
PEG (NY)N/A
PEG (5Y)3.64
Graham Number15.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.54% | ||
| ROE | -3.82% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.24% | ||
| FCFM | N/A |
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
F-Score7
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 88.3% | ||
| Cap/Sales | 6.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.01 | ||
| Quick Ratio | 7.01 | ||
| Altman-Z | 6.09 |
F-Score7
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)101.39%
Cap/Depr(5y)338.11%
Cap/Sales(3y)8.31%
Cap/Sales(5y)7.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.27%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-54.84%
EPS Next Y-41.71%
EPS Next 2Y-63.28%
EPS Next 3Y-32.37%
EPS Next 5Y-24.95%
Revenue 1Y (TTM)13.6%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%17.18%
Revenue Next Year14.59%
Revenue Next 2Y12.14%
Revenue Next 3Y11.38%
Revenue Next 5Y10.99%
EBIT growth 1Y19.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.23%
EBIT Next 3Y26.85%
EBIT Next 5Y26.55%
FCF growth 1Y-192.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.64%
OCF growth 3Y-66.06%
OCF growth 5Y30.8%
FULGENT GENETICS INC / FLGT FAQ
Can you provide the ChartMill fundamental rating for FULGENT GENETICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to FLGT.
Can you provide the valuation status for FULGENT GENETICS INC?
ChartMill assigns a valuation rating of 0 / 10 to FULGENT GENETICS INC (FLGT). This can be considered as Overvalued.
Can you provide the profitability details for FULGENT GENETICS INC?
FULGENT GENETICS INC (FLGT) has a profitability rating of 2 / 10.
Can you provide the financial health for FLGT stock?
The financial health rating of FULGENT GENETICS INC (FLGT) is 6 / 10.
Can you provide the expected EPS growth for FLGT stock?
The Earnings per Share (EPS) of FULGENT GENETICS INC (FLGT) is expected to decline by -41.71% in the next year.